MoonLake Immunotherapeutics - Class A Ordinary Shares —— 季度资产负债表 (NASDAQ:MLTX) | MetaTrader

展开完整图表完整图表

新闻

MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket

Clear Street上调Moonlake目标价,看好IL-17数据

Clear Street raises Moonlake stock price target on IL-17 data

Cantor Fitzgerald重申Moonlake股票评级,看好强直性脊柱炎市场潜力

Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential

H.C. Wainwright基于试验结果将Moonlake Immunotherapeutics目标价上调至40美元

Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake股价因axSpA试验数据积极而飙升

MoonLake stock surges on positive axSpA trial data